Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgerySierra Health and Life Leqembi Coverage Update | O…
    Ask Trek AI about this page
    Currentsierra health and lifePolicy 2026D0125E

    Leqembi (lecanemab-irmb) intravenous infusion — coverage criteria

    Customize your policy alerts

    Sign up for sierra health and life Policy 2026D0125E alerts

    Get alerted when Policy 2026D0125E changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical benefit policy governing coverage and prior authorization criteria for Leqembi (lecanemab-irmb) IV infusion for the treatment of Alzheimer's disease for Sierra Health and Life / UnitedHealthcare Commercial members.

    Policy Summary
    Payersierra health and life
    PolicyLeqembi (lecanemab-irmb) intravenous infusion — coverage criteria
    Policy CodePolicy 2026D0125E
    Change TypeAdministrative: applicable HCPCS code update
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization; initial and reauthorization approvals are limited to no more than 12 months.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Updated list of applicable HCPCS codes and revised description for J0174.

    J0174HCPCS code listed for lecanemab-irmb
    10 mg/kg q2wDose / regimen
    MMSE 20-30Cognitive test ranges
    ≤12 monthsBaseline MRI timing
    ExcludedCombination therapy
    12 monthsMax authorization period

    Coverage Criteria for Leqembi (lecanemab-irmb)

    Initial Therapy

    Leqembi is covered when ALL of the following are met for initial therapy:

    Diagnostic criteria: Diagnosis of mild cognitive impairment (MCI) due to Alzheimer’s disease OR mild dementia due to Alzheimer’s disease based on NIA-AA criteria.
    Biomarker confirmation: Presence of brain amyloid beta pathology confirmed by positive amyloid PET OR CSF biomarker testing consistent with beta-amyloid accumulation (e.g., abnormal Aβ42/40 ratio, p-tau181/Aβ42, or t-tau/Aβ42).
    Baseline imaging: Baseline brain magnetic resonance imaging (MRI) completed within 12 months prior to initiating treatment.
    Anticoagulation considerations: Either patient is not currently taking an anticoagulant OR if taking an anticoagulant, counseling has been provided about increased risk of cerebral macrohemorrhage and prescriber attests shared decision-making occurred.
    Combination therapy exclusion: Not used in combination with other amyloid-beta monoclonal antibodies for Alzheimer’s disease (e.g., Kisunla).
    Prescriber and dosing: Prescribed by a neurologist, geriatric psychiatrist, or geriatrician who specializes in treating dementia AND dosing consistent with FDA-approved labeling (e.g., the regimen studied: 10 mg/kg IV every 2 weeks).10 mg/kg every 2 weeks
    Authorization duration: Initial authorization will be for no more than 12 months.
    Documentation and differential diagnosis: Other causes of cognitive impairment (e.g., DLB, FTD, vascular dementia, reversible causes) have been ruled out and required medical records (chart notes, labs, imaging) are submitted to support initiation.

    Continuation Therapy

    For continuation of therapy, ALL of the following must be met:

    Ongoing diagnosis: Diagnosis of Alzheimer’s disease (continued indication for therapy).
    Follow-up imaging: Submission of medical records confirming follow-up brain MRI completed after initiation of therapy.

    ARIA assessment after initiation

    • No ARIA observed: ARIA has not been observed on follow-up MRI.
    • ARIA observed with resolution/stability or prescriber attestation: ARIA has been observed on MRI; prescriber attests continuation of therapy is appropriate based on clinical severity AND either follow-up MRI demonstrates radiographic resolution or stabilization, or prescriber attests continuation is appropriate based on radiographic severity of ARIA.

    Unproven / Not Medically Necessary

    Other indications: Leqembi (lecanemab-irmb) is unproven and not medically necessary for any indication other than Alzheimer’s disease.

    Initial therapy coverage criteria

    Covered when ALL of the following are met (policy references clinical trial population and FDA indication):

    Population and diagnostic confirmation: Patient has mild cognitive impairment or mild dementia consistent with early Alzheimer’s disease AND has evidence of brain amyloid pathology as required in the clinical trials (positive amyloid PET or CSF).
    Treatment regimen: Planned use of lecanemab at the regimen studied in trials or per FDA labeling.10 mg/kg every 2 weeks
    Trial-aligned baseline characteristics: Clinical characteristics align with trial populations (e.g., baseline cognitive staging consistent with early AD as in CLARITY AD).
    Benefit plan and mandates: Member-specific benefit plan allows coverage for this drug for the indication OR applicable state/federal mandates apply (consult benefit document).

    Use of Leqembi in combination with other amyloid‑beta (Aβ) monoclonal antibodies (for example, Kisunla) is explicitly excluded and will trigger denial of coverage. The policy requires that Leqembi not be administered concomitantly with other Aβ mAbs for both initial and continuation therapy determinations.

    FDA approval for Leqembi is provided for informational purposes only. FDA approval alone is not a basis for coverage; coverage decisions are determined by the member‑specific benefit plan document and any applicable state or federal mandates, which may supersede policy language.

    Leqembi is considered unproven and not medically necessary for any indication other than Alzheimer's disease. Coverage and medical necessity determinations are limited to the FDA‑indicated population (mild cognitive impairment or mild dementia due to Alzheimer's disease) and uses outside that indication are not supported by the policy.

    Prior failures of investigational anti‑Aβ therapies have frequently been associated with treatment of patients who lacked biomarker confirmation of amyloid pathology or who were enrolled at later stages of disease when irreversible neurodegeneration was more advanced. As a result, the policy requires documentation of biomarker‑confirmed Aβ pathology (amyloid PET or CSF) and limits treatment to the early AD population—conditions intended to avoid repeating factors that contributed to prior negative trials.

    Coding and Diagnostic Codes

    Applicable HCPCSHCPCS
    J0174Lecanemab-irmb, for intravenous injection, 1 mg.
    Relevant Diagnosis CodesICD-10
    G30.0Alzheimer's disease with early onset.
    G30.1Alzheimer's disease with late onset.
    G30.8Other Alzheimer's disease.
    G30.9Alzheimer's disease, unspecified
    Applicable HCPCS (not exhaustive here — policy updates codes)HCPCS
    J0174Updated description for J0174 per applicable codes list
    Cognitive test score ranges — acceptable tests and documented ranges
    MMSE20–30
    MoCA17–30
    SLUMS17–30
    Baseline MRI timing — imaging requirements
    Baseline brain MRI timingCompleted within 12 months prior to initiating treatment
    Follow-up MRI (continuation)Follow-up brain MRI completed after initiation of therapy (required for reauthorization)
    MRI purpose

    Provider Actions, Prior Authorization, and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Leqembi (lecanemab-irmb). Initial and reauthorization approvals are limited to no more than 12 months. Treatment must align with the FDA-indicated population (patients with mild cognitive impairment or mild dementia due to Alzheimer's disease) and member-level eligibility requirements in the criteria. Providers must consult the member-specific benefit plan document to determine coverage, step therapy, or exceptions, as the benefit document governs coverage decisions and may supersede this policy where applicable.

    • Initial authorization: ≤ 12 months
    • Reauthorization: ≤ 12 months
    • Treatment initiation population: mild cognitive impairment or mild dementia (per FDA/CLARITY AD)
    • Benefit document supersedes policy where applicable
    Documentation Required

    Documentation Required for Continuation of Therapy

    Background

    Alzheimer's disease is characterized by abnormal accumulation of amyloid‑beta (Aβ) plaques and neurofibrillary tangles of tau. Amyloid deposition typically begins decades before clinical symptoms emerge; abnormal Aβ can be detected with amyloid PET or CSF biomarkers, and CSF p‑tau and t‑tau are also used to support a diagnosis in patients with mild cognitive impairment. The policy aligns treatment with the pathophysiology and trial populations by requiring evidence of Aβ pathology prior to initiating therapy.

    Definitions and Key Terms

    Leqembi (lecanemab-irmb) — drug description
    Molecular classHumanized IgG1 monoclonal antibody
    TargetAggregated soluble and insoluble forms of amyloid beta (Aβ)
    Pathophysiologic rationaleTargets Aβ plaque accumulation, a defining feature of Alzheimer's disease
    Indicated diagnosis — FDA/study-aligned definitions
    Indicated populationsMild cognitive impairment (MCI) due to Alzheimer's disease; Mild dementia due to Alzheimer's disease
    Diagnostic basisDiagnosis based on National Institute on Aging and Alzheimer's Association (NIA-AA) criteria
    Biomarker requirement

    Revision History and Policy Changes

    2026-04-01administrativeLatest

    Administrative quarterly edit to applicable HCPCS codes and revised description for J0174; previous policy version 2026D0125D archived.

    Policy Summary
    Payersierra health and life
    PolicyLeqembi (lecanemab-irmb) intravenous infusion — coverage criteria
    Policy CodePolicy 2026D0125E
    Change TypeAdministrative: applicable HCPCS code update
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization; initial and reauthorization approvals are limited to no more than 12 months.
    SourceLink
    On This Page
    Coverage Criteria for Leqembi (lecanemab-irmb)Coding and Diagnostic CodesProvider Actions, Prior Authorization, and Documentation RequirementsBackgroundDefinitions and Key TermsRevision History and Policy Changes
    Combination therapy exclusion: Not used in combination with other amyloid-beta monoclonal antibodies for Alzheimer’s disease (e.g., Kisunla).
    Prescriber and dosing: Prescribed by a neurologist, geriatric psychiatrist, or geriatrician who specializes in treating dementia AND dosing consistent with FDA-approved labeling.
    Reauthorization duration: Reauthorization is for no more than 12 months.
    Documentation required: Submission of medical records documenting follow-up MRI results and documentation regarding presence, resolution, stabilization, and prescriber rationale for continuation when ARIA was observed.
    Documentation of trial-relevant data: Clinical documentation (e.g., cognitive scores, amyloid confirmation, baseline MRI) sufficient to demonstrate the patient matches the clinical trial population and FDA-indicated population.
    Assess baseline hemorrhage, ARIA risk and provide comparator for subsequent imaging
    Effective dose determination in Study 201 (ED90)
    ED90 definitionThe simplest dose that achieves ≥ 90% of the maximum treatment effect (effective dose 90)
    Dose identified in Study 201 (ED90)10 mg/kg IV every 2 weeks (biweekly)
    Study design contextDerived from Study 201, an 18-month Phase 2b randomized trial designed to establish ED90

    Providers must submit documentation to support continuation (reauthorization) of therapy, including evidence of ongoing benefit and safety monitoring. Required items include follow-up brain MRI after treatment initiation and documentation that continued use is appropriate given MRI findings and clinical status. If ARIA is observed, prescriber attestation regarding appropriateness of continuation and evidence of radiographic resolution/stability or clinical justification must be provided.

    • Follow-up brain MRI completed after initiation of therapy
    • Documentation of continued clinical benefit and safety monitoring
    • If ARIA observed: prescriber attestation that continuation is appropriate and evidence of radiographic resolution/stabilization or clinical justification
    Documentation Required

    Required Documentation for Initial Therapy

    Submit medical records documenting cognitive testing and confirmation of amyloid pathology as part of the initial authorization. Documentation should include standardized cognitive scores and one or more amyloid biomarker results.

    • Cognitive testing: MMSE 20–30 or MoCA 17–30 or SLUMS 17–30
    • Amyloid evidence: positive amyloid PET OR CSF biomarker abnormalities (e.g., Aβ42/40 ratio, ptau181/Aβ42, ttau/Aβ42)
    • Differential diagnoses ruled out in documentation
    Note

    Clinical Trial Evidence to Document

    Clinical trial evidence should be provided or referenced to document that the member matches trial populations and expected endpoints. CLARITY AD enrolled patients with early Alzheimer's disease (MCI or mild dementia) with amyloid confirmation and used CDR‑SB, ADAS‑cog14, ADCOMS, and ADCS‑MCI‑ADL as endpoints. Safety signals (ARIA‑E, ARIA‑H, infusion reactions) observed in trials should be considered in risk counseling and documentation.

    • Trial population: early AD (MCI or mild dementia), age 50–90, amyloid positive
    • Key endpoints: CDR‑SB primary; ADAS‑cog14, ADCOMS, ADCS‑MCI‑ADL secondary
    • Safety signals to document: ARIA‑E (≈12.5%), ARIA‑H (≈17%), infusion reactions (≈26%)
    Step Therapy

    Plan-Determined Step Requirements and Benefit Routing

    Benefit plans may impose step therapy, experimental/investigational exclusions, or allow investigational coverage for life‑threatening conditions. Providers must review member-specific benefit documents to determine whether step requirements apply, whether Leqembi is routed to the pharmacy or medical benefit, and whether experimental/unproven exclusions are overridden by the member's certificate of coverage or applicable state mandates.

    • Leqembi IQLIK (subcutaneous) generally billed under pharmacy benefit unless member plan specifies otherwise
    • IV Leqembi billed under the medical benefit
    • Member-specific benefit document determines step therapy and investigational coverage; state mandates may supersede
    Presence of amyloid beta pathology must be confirmed (amyloid PET or CSF)
    Numeric Clinical Staging (Alzheimer's continuum) — Stages 0–6 summary
    Stage 0Asymptomatic; biomarkers normal; no clinical change
    Stage 2Transitional decline: mild detectable change, minimal impact on daily function
    Stage 3Cognitive impairment with early functional impact; impaired range on objective tests but independent on basic ADLs
    Stage 4–6 (summary)Stage 4: mild functional impairment; Stage 5: moderate functional impairment requiring assistance; Stage 6: severe impairment with complete dependence
    Lecanemab / Leqembi — alternate names and brief descriptor
    Alternate nameLecanemab (generic); Leqembi (brand, lecanemab-irmb)
    Class descriptionHumanized IgG1 monoclonal antibody directed against aggregated soluble and insoluble amyloid beta
    Approved use contextStudied and FDA-indicated for treatment of early Alzheimer's disease (MCI or mild dementia) with confirmed amyloid pathology